Analysis of serum angiogenic factors in a young multiple myeloma patient with high-output cardiac failure

International Journal of Hematology

Volumn 86, Issue 1, 2007, Pages 72-76

  Sasaki, Kazunari ^a   Yamashita, Kouhei ^a   Miyoshi, Takashi ^a   Furukawa, Yutaka ^a   Kimura, Takeshi ^a   Kita, Toru ^a   Ichinohe, Tatsuo ^a   Ishikawa, Takayuki ^a   Sasada, Masataka ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Angiogenic factors; Cytokines; High output cardiac failure; Multiple myeloma

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MELPHALAN; SOMATOMEDIN BINDING PROTEIN 6; VINCRISTINE;

ADULT; ANGIOGENESIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER PATIENT; CASE REPORT; CORONARY BLOOD VESSEL; DRUG MEGADOSE; HIGH OUTPUT HEART FAILURE; HUMAN; MALE; MULTIPLE MYELOMA; PATHOGENESIS; PROTEIN BLOOD LEVEL; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANGIOGENESIS INDUCING AGENTS; CYTOKINES; HEART FAILURE; HUMANS; MALE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34547615950     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06226     Document Type: Article

References (19)

1. Tamir R, Lewin RF, Inbal A, Heller I, Theodor E. High-output cardiac failure as a presenting symptom of plasma cell leukemia. Isr J Med Sci. 1985;21:679-682.
2. High-output cardiac failure in multiple myeloma. N Engl J Med. 1989;320:1419-1420.
3. Kosinski DJ, Roush K, Fraker TD Jr, Grubb BP. High cardiac output state in patients with multiple myeloma: case report and review of the literature. Clin Cardiol. 1994;17:678-680.
4. Goncalvesova E, Uhliarikova E, Vahancik A, Kohn R, Gyarfas J. Hypercirculatory heart failure in a patient with plasmacytic leukemia [in Slovak]. Vnitr Lek. 1995;41:773-776.
5. Kuribayashi N, Matsuzaki H, Hata H, et al. Multiple myeloma associated with serum amino acid disturbance and high output cardiac failure. Am J Hematol. 1998;57:77-81.
6. McBride W, Jackman JD Jr, Gammon RS, Willerson JT. High-output cardiac failure in patients with multiple myeloma. N Engl J Med. 1988;319:1651-1653.
7. Sanchez FW, Chuang VP, Skolkin MD. Transcatheter treatment of myelomatous AV shunting causing high-output failure. Cardiovasc Intervent Radiol 1986;9:219-221.
8. Iwasaki T, Sano H. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels. Leuk Lymphoma. 2003;44:1347-1351.
9. McBride W, Jackman JD Jr, Grayburn PA. Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma. Am J Med. 1990;89:21-24.
10. Judson IR, Gore ME, Tighe J, Nicolson M, McElwain TJ. Resolution of high-output cardiac failure following treatment of multiple myeloma. N Engl J Med. 1989;321:1685-1686.
11. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93:345-351.
12. Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica. 2003;88:113-115.
13. Colla S, Roti G, Rizzoli V, Giuliani N. Angiopoietins expression by human myeloma cells. Haematologica. 2003;88:ELT20, author reply ELT21.
14. Giuliani N, Colla S, Lazzaretti M, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 2003;102:638-645.
15. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol. 2004;43:423-428.
16. Funahashi H, Okada Y, Sawai H, et al. The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells. J Surg Oncol. 2005;91:77-83.
17. Bach LA. IGFBP-6 five years on; not so 'forgotten'? Growth Horm IGF Res. 2005;15:185-192.
18. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824-854.
19. Nordqvist AC, Mathiesen T. Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness. J Neurooncol. 2002;57:19-26.